N-ethylmorpholinium acetate | 108681-29-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-ethylmorpholinium acetate
• 英文别名: N-ethylmorpholine acetate；4-ethylmorpholin-4-ium;acetate
• CAS: 108681-29-4
• 化学式: C₂H₄O₂*C₆H₁₃NO
• 分子量: 175.228
• InChiKey: HPGXYQZKIMWRAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.43
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-乙基吗啉 、 溶剂黄146 反应 24.0h， 生成 N-ethylmorpholinium acetate
  参考文献：
  名称：

  质子吗啉基离子液体表面性质的实​​验研究

  摘要：

  在这项工作中，合成了十种具有烷基羧酸根阴离子的新型质子吗啉基离子液体（ILs），其密度和表面张力的测量范围为298.15至348.15K。该设备有助于在水含量极低且没有水蒸气的情况下在液/气界面进行测量。在相同条件下也测量了弯液面接触角。每个IL的表面张力表现出与温度的高度线性相关性，从而可以准确评估表面热力学函数（表面熵和表面能）。根据表面张力值，通过古根希姆（Guggenhiem）和Eötvös方程估算临界点。表面张力，

  DOI：

  10.1016/j.molliq.2017.06.045
• 作为试剂：
  描述：

  2,2-二溴乙醇 、 胞苷 在 N-ethylmorpholinium acetate 作用下， 反应 168.0h， 生成 N³,4-ethenocytidine hydrochloride
  参考文献：
  名称：

  Formation of etheno adducts of adenosine and cytidine from 1-halooxiranes. Evidence for a mechanism involving initial reaction with the endocyclic nitrogen atoms

  摘要：

  The etheno derivatives of nucleic acid bases contain an additional ring and are of interest because of their useful fluorescence properties and their potential as mutagenic lesions in DNA. The mechanism of formation from 2-haloacetaldehydes is known to involve initial Schiff base formation at an exocyclic nitrogen; however, mechanisms of formation from the more relevant 1-substituted oxiranes have not been established. The reaction of N6-methyladenosine (5) with 1-chlorooxirane yielded the stable carbinolamine 7,8-dihydro-8-hydroxy-9-methyl-3-beta-D-ribofuranosylimidazo[2,1-i]purinium species (10), consistent with initial attack of the N1 atom of adenine at the methylene of 1-chlorooxirane. No products indicative of initial reaction at the N6 atom of adenine were found. Reaction of 2,2-dibromoethanol with adenosine or cytidine at pH 9.2 yielded 1,N6-ethenoadenosine (1) or 3,N4-ethenocytidine (2), respectively, presumably via the base-catalyzed formation of 1-bromooxirane from the bromohydrin. When reactions were done with 2,2-dibromo[1-C-13]ethanol, 1 contained label only at C-7 and 2 contained label only at C-3. A role for 2-bromoacetaldehyde in these reactions was ruled out by the lack of incorporation of deuterium from (H2O)-H-2 into 1 under conditions where the exchange of the methylene protons of 2-bromoacetaldehyde with the solvent was relatively rapid. The collective results are most consistent with a mechanism in which the basic endocyclic nitrogen (N1 of adenine or N3 of cytosine) reacts with the methylene carbon of the 1-halooxirane, and, after ring opening and loss of the leaving group, the resulting aldehyde reacts with the exocyclic nitrogen to form the additional ring.

  DOI：

  10.1021/ja00029a041

文献信息

• Study on absorption and spectral properties of H2S in carboxylate protic ionic liquids with low viscosity
  作者：Tianxiang Zhao、Ping Li、Xi Feng、Xingbang Hu、Youting Wu

  DOI：10.1016/j.molliq.2018.07.011

  日期：2018.9

  Here we synthesized ten carboxylate protic ionic liquids (PILs), containing N-ethylmorpholine acetate, N-ethylmorpholine propionate, N-ethylmorpholine butyrate, N-ethylmorpholine methoxylacetate, 4-(2-hydroxyethyl) morpholine acetate, and 4-(2-hydroxyethyl) morpholine methoxyacetate, triethylamine acetate, triethylamine propionate, triethylamine propionate, and triethylamine methoxylacetate, with low

  高昂的价格和高粘度是离子液体（IL）的两个主要缺点，这会影响离子液体在气体分离中的实际应用。在这里，我们合成了10羧酸质子型离子液体（比尔森），含Ñ醋酸-ethylmorpholine，Ñ -ethylmorpholine丙酸酯，Ñ -ethylmorpholine丁酸Ñ -ethylmorpholine methoxylacetate，4-（2-羟乙基）吗啉乙酸盐，和4-（2-羟基乙基）吗啉甲氧基乙酸盐，乙酸三乙胺，丙酸三乙胺，丙酸三乙胺和甲氧基乙酸三乙胺，具有吸收H 2的低成本和高粘度S.在大气压下在（298.2至333.2）K的温度范围内测量这些羧酸盐PIL的密度和粘度。使用等容饱和技术在298.2–318.2 K和0–1.096 bar下测定H 2 S在这些PIL中的溶解度。发现H 2 S在这些PIL中的溶解度随着羧酸上烷基链的压力和长度的增加而增加。在给定的实验条件下，吸收过程遵
• Lacklösungen auf der Basis von Hydantoingruppen enthaltenden Polymeren und ihre Verwendung
  申请人：BAYER AG

  公开号：EP0150440A2

  公开（公告）日：1985-08-07

  Die Erfindung betrifft neue Drahtlacke auf der Basis von Hydantoingruppen enthaltenden Polymeren.

  本发明涉及以含有海因基团的聚合物为基础的新型漆包线漆。
• Monoclonal antibodies against interferon-induced human protein in pure form, and test kits containing these antibodies
  申请人：CIBA-GEIGY AG

  公开号：EP0242329A2

  公开（公告）日：1987-10-21

  The invention relates to purified proteins induced in human cells by interferon a or β, RNAs, DNAs and hybrid vectors coding for said proteins, hosts transformed with such a hybrid vector, processes for the preparation and purification of these proteins, DNAs, vectors and hosts, monoclonal antibodies specific to these proteins, monoclonal antibody derivatives, hybridoma cell lines secreting these monoclonal antibodies, the use of the monoclonal antibodies and their derivatives in the qualitative and quantitative determination of these proteins, test kits containing the monoclonal antibodies, and pharmaceutical preparations containing said proteins. A protein of the invention shows antiviral properties ascribed to interferons and may be a valuable indicator of the cell response to an interferon therapy.

  本发明涉及干扰素 a 或 β 在人体细胞中诱导的纯化蛋白质，编码上述蛋白质的 RNA、DNA 和杂交载体，用这种杂交载体转化的宿主，制备和纯化这些蛋白质、DNA、载体和宿主的工艺，针对这些蛋白质的特异性单克隆抗体、单克隆抗体衍生物、分泌这些单克隆抗体的杂交瘤细胞系、使用单克隆抗体及其衍生物对这些蛋白质进行定性和定量测定、含有单克隆抗体的检测试剂盒以及含有上述蛋白质的药物制剂。本发明的一种蛋白质具有干扰素的抗病毒特性，可作为细胞对干扰素疗法反应的重要指标。
• Oligopeptid-Antibiotika
  申请人：CIBA-GEIGY AG

  公开号：EP0263502A2

  公开（公告）日：1988-04-13

  Rhizocticine der Formel worin X Wasserstoff oder einen hydrophoben Aminosäurerest und Y einen basischen Aminosäurerest bedeuten, wobei die C2-Atome der Aminosäurereste die L-Konfiguration besitzen, sowie geschützte Derivate und Salze davon. Die Verbindungen werden aus Kulturbrühen von Bacillus subtilis oder synthetisch gewonnen und haben insbesondere fungizide Wirkung.

  式中 其中 X 为氢或疏水氨基酸残基，Y 为碱性氨基酸残基，氨基酸残基的 C2 原子为 L 构型，以及其保护衍生物和盐。 这些化合物可从枯草芽孢杆菌的培养液中获得或人工合成，尤其具有杀菌活性。
• Human thymopoietin
  申请人：ORTHO PHARMACEUTICAL CORPORATION

  公开号：EP0300741A2

  公开（公告）日：1989-01-25

  The present invention relates to human thymopoietin substantially free of non-human thymopoietin native matter, to therapeutic compositions containing it and to the use of such thymopoietin or compositions in modulating the immune system.

  本发明涉及基本上不含非人类胸腺生成素原生物质的人类胸腺生成素、含有胸腺生成素的治疗组合物，以及使用这种胸腺生成素或组合物调节免疫系统。